Top

Published in:

Open Access 01-12-2011 | Review

Vaccines targeting the neovasculature of tumors

Authors: Agata Matejuk, Qixin Leng, Szu-Ting Chou, Archibald J Mixson

Published in: Vascular Cell | Issue 1/2011

Abstract

Angiogenesis has a critical role in physiologic and disease processes. For the growth of tumors, angiogenesis must occur to carry sufficient nutrients to the tumor. In addition to growth, development of new blood vessels is necessary for invasion and metastases of the tumor. A number of strategies have been developed to inhibit tumor angiogenesis and further understanding of the interplay between tumors and angiogenesis should allow new approaches and advances in angiogenic therapy. One such promising angiogenic approach is to target and inhibit angiogenesis with vaccines. This review will discuss recent advances and future prospects in vaccines targeting aberrant angiogenesis of tumors. The strategies utilized by investigators have included whole endothelial cell vaccines as well as vaccines with defined targets on endothelial cells and pericytes of the developing tumor endothelium. To date, several promising anti-angiogenic vaccine strategies have demonstrated marked inhibition of tumor growth in pre-clinical trials with some showing no observed interference with physiologic angiogenic processes such as wound healing and fertility.

Available only for authorised users

Rosen LS: Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers. Cancer Control. 2002, 9: 36-44.PubMed

Gordan JD, Simon MC: Hypoxia-inducible factors: central regulators of the tumor phenotype. Curr Opin Genet Dev. 2007, 17: 71-77. 10.1016/j.gde.2006.12.006.PubMedCentralPubMed

Gruber M, Simon MC: Hypoxia-inducible factors, hypoxia, and tumor angiogenesis. Curr Opin Hematol. 2006, 13: 169-174. 10.1097/01.moh.0000219663.88409.35.PubMed

Search for Clinical Trials-National Cancer Institute. [http://www.cancer.gov/clinicaltrials/search]

Fens MH, Storm G, Schiffelers RM: Tumor vasculature as target for therapeutic intervention. Expert Opin Investig Drugs. 2010, 19: 1321-1338. 10.1517/13543784.2010.524204.PubMed

Tammela T, Zarkada G, Wallgard E, Murtomaki A, Suchting S, Wirzenius M, Waltari M, Hellstrom M, Schomber T, Peltonen R, et al: Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature. 2008, 454: 656-660. 10.1038/nature07083.PubMed

Hu B, Cheng SY: Angiopoietin-2: development of inhibitors for cancer therapy. Curr Oncol Rep. 2009, 11: 111-116. 10.1007/s11912-009-0017-3.PubMedCentralPubMed

Chen QR, Zhang L, Gasper W, Mixson AJ: Targeting tumor angiogenesis with gene therapy. Mol Genet Metab. 2001, 74: 120-127. 10.1006/mgme.2001.3223.PubMed

Cao Y: Off-tumor target--beneficial site for antiangiogenic cancer therapy?. Nat Rev Clin Oncol. 2010, 7: 604-608. 10.1038/nrclinonc.2010.118.PubMed

10.

Cao Y: Angiogenesis: What can it offer for future medicine?. Exp Cell Res. 2010, 316: 1304-1308. 10.1016/j.yexcr.2010.02.031.PubMed

11.

Cao Y, Langer R: Optimizing the delivery of cancer drugs that block angiogenesis. Sci Transl Med. 2010, 2: 15ps13-

12.

St Croix B, Rago C, Velculescu V, Traverso G, Romans KE, Montgomery E, Lal A, Riggins GJ, Lengauer C, Vogelstein B, Kinzler KW: Genes expressed in human tumor endothelium. Science. 2000, 289: 1197-1202. 10.1126/science.289.5482.1197.PubMed

13.

Seaman S, Stevens J, Yang MY, Logsdon D, Graff-Cherry C, St Croix B: Genes that distinguish physiological and pathological angiogenesis. Cancer Cell. 2007, 11: 539-554. 10.1016/j.ccr.2007.04.017.PubMedCentralPubMed

14.

Boehm T, Folkman J, Browder T, O'Reilly MS: Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature. 1997, 390: 404-407. 10.1038/37126.PubMed

15.

Huang J, Soffer SZ, Kim ES, McCrudden KW, New T, Manley CA, Middlesworth W, O'Toole K, Yamashiro DJ, Kandel JJ: Vascular remodeling marks tumors that recur during chronic suppression of angiogenesis. Mol Cancer Res. 2004, 2: 36-42.PubMed

16.

Hida K, Hida Y, Amin DN, Flint AF, Panigrahy D, Morton CC, Klagsbrun M: Tumor-associated endothelial cells with cytogenetic abnormalities. Cancer Res. 2004, 64: 8249-8255. 10.1158/0008-5472.CAN-04-1567.PubMed

17.

Hida K, Klagsbrun M: A new perspective on tumor endothelial cells: unexpected chromosome and centrosome abnormalities. Cancer Res. 2005, 65: 2507-2510. 10.1158/0008-5472.CAN-05-0002.PubMed

18.

Ricci-Vitiani L, Pallini R, Biffoni M, Todaro M, Invernici G, Cenci T, Maira G, Parati EA, Stassi G, Larocca LM, De Maria R: Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature. 2010, 468: 824-828. 10.1038/nature09557.PubMed

19.

Wang R, Chadalavada K, Wilshire J, Kowalik U, Hovinga KE, Geber A, Fligelman B, Leversha M, Brennan C, Tabar V: Glioblastoma stem-like cells give rise to tumour endothelium. Nature. 2010, 468: 829-833. 10.1038/nature09624.PubMed

20.

Folkman J: Fighting cancer by attacking its blood supply. Sci Am. 1996, 275: 150-154. 10.1038/scientificamerican0996-150.PubMed

21.

Folkman J: Antiangiogenic Therapy. Principles and Practice of Oncology. Edited by: DeVita VT, Hellman S, Rosenberg SA. 1997, Philadelphia: Lippincott-Raven, 3075-3085.

22.

Hurwitz H: Integrating the anti-VEGF-A humanized monoclonal antibody bevacizumab with chemotherapy in advanced colorectal cancer. Clin Colorectal Cancer. 2004, 4 (Suppl 2): S62-68. 10.3816/CCC.2004.s.010.PubMed

23.

Eskens FA, Sleijfer S: The use of bevacizumab in colorectal, lung, breast, renal and ovarian cancer: where does it fit?. Eur J Cancer. 2008, 44: 2350-2356. 10.1016/j.ejca.2008.07.042.PubMed

24.

Grothey A, Ellis LM: Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies. Cancer J. 2008, 14: 170-177. 10.1097/PPO.0b013e318178d9de.PubMed

25.

Chaudhuri D, Suriano R, Mittelman A, Tiwari RK: Targeting the immune system in cancer. Curr Pharm Biotechnol. 2009, 10: 166-184. 10.2174/138920109787315114.PubMed

26.

Palena C, Schlom J: Vaccines against human carcinomas: strategies to improve antitumor immune responses. J Biomed Biotechnol. 2010, 2010: 380697-PubMedCentralPubMed

27.

Fioretti D, Iurescia S, Fazio VM, Rinaldi M: DNA vaccines: developing new strategies against cancer. J Biomed Biotechnol. 2010, 2010: 174378-PubMedCentralPubMed

28.

Chiang CL, Benencia F, Coukos G: Whole tumor antigen vaccines. Semin Immunol. 2010, 22: 132-143. 10.1016/j.smim.2010.02.004.PubMedCentralPubMed

29.

Signori E, Iurescia S, Massi E, Fioretti D, Chiarella P, De Robertis M, Rinaldi M, Tonon G, Fazio VM: DNA vaccination strategies for anti-tumour effective gene therapy protocols. Cancer Immunol Immunother. 2010, 59: 1583-1591. 10.1007/s00262-010-0853-x.PubMed

30.

Reisfeld RA, Niethammer AG, Luo Y, Xiang R: DNA vaccines designed to inhibit tumor growth by suppression of angiogenesis. Int Arch Allergy Immunol. 2004, 133: 295-304. 10.1159/000077009.PubMed

31.

Gravekamp C, Paterson Y: Harnessing Listeria monocytogenes to target tumors. Cancer Biol Ther. 2010, 9: 257-265.PubMed

32.

Seavey MM, Maciag PC, Al-Rawi N, Sewell D, Paterson Y: An anti-vascular endothelial growth factor receptor 2/fetal liver kinase-1 Listeria monocytogenes anti-angiogenesis cancer vaccine for the treatment of primary and metastatic Her-2/neu+ breast tumors in a mouse model. J Immunol. 2009, 182: 5537-5546. 10.4049/jimmunol.0803742.PubMedCentralPubMed

33.

Maciag PC, Seavey MM, Pan ZK, Ferrone S, Paterson Y: Cancer immunotherapy targeting the high molecular weight melanoma-associated antigen protein results in a broad antitumor response and reduction of pericytes in the tumor vasculature. Cancer Res. 2008, 68: 8066-8075. 10.1158/0008-5472.CAN-08-0287.PubMedCentralPubMed

34.

Kaplan CD, Kruger JA, Zhou H, Luo Y, Xiang R, Reisfeld RA: A novel DNA vaccine encoding PDGFRbeta suppresses growth and dissemination of murine colon, lung and breast carcinoma. Vaccine. 2006, 24: 6994-7002. 10.1016/j.vaccine.2006.04.071.PubMed

35.

Xiang R, Mizutani N, Luo Y, Chiodoni C, Zhou H, Mizutani M, Ba Y, Becker JC, Reisfeld RA: A DNA vaccine targeting survivin combines apoptosis with suppression of angiogenesis in lung tumor eradication. Cancer Res. 2005, 65: 553-561.PubMed

36.

Daudel D, Weidinger G, Spreng S: Use of attenuated bacteria as delivery vectors for DNA vaccines. Expert Rev Vaccines. 2007, 6: 97-110. 10.1586/14760584.6.1.97.PubMed

37.

Lladser A, Ljungberg K, Tufvesson H, Tazzari M, Roos AK, Quest AF, Kiessling R: Intradermal DNA electroporation induces survivin-specific CTLs, suppresses angiogenesis and confers protection against mouse melanoma. Cancer Immunol Immunother. 2010, 59: 81-92. 10.1007/s00262-009-0725-4.PubMed

38.

Holmgren L, Ambrosino E, Birot O, Tullus C, Veitonmaki N, Levchenko T, Carlson LM, Musiani P, Iezzi M, Curcio C, et al: A DNA vaccine targeting angiomotin inhibits angiogenesis and suppresses tumor growth. Proc Natl Acad Sci USA. 2006, 103: 9208-9213. 10.1073/pnas.0603110103.PubMedCentralPubMed

39.

Lladser A, Parraga M, Quevedo L, Carmen Molina M, Silva S, Ferreira A, Billetta R, AF GQ: Naked DNA immunization as an approach to target the generic tumor antigen survivin induces humoral and cellular immune responses in mice. Immunobiology. 2006, 211: 11-27. 10.1016/j.imbio.2005.08.002.PubMed

40.

Zhu K, Qin H, Cha SC, Neelapu SS, Overwijk W, Lizee GA, Abbruzzese JL, Hwu P, Radvanyi L, Kwak LW, Chang DZ: Survivin DNA vaccine generated specific antitumor effects in pancreatic carcinoma and lymphoma mouse models. Vaccine. 2007, 25: 7955-7961. 10.1016/j.vaccine.2006.10.026.PubMed

41.

Nanni P, Nicoletti G, De Giovanni C, Landuzzi L, Di Carlo E, Cavallo F, Pupa SM, Rossi I, Colombo MP, Ricci C, et al: Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice. J Exp Med. 2001, 194: 1195-1205. 10.1084/jem.194.9.1195.PubMedCentralPubMed

42.

Hu B, Wei Y, Tian L, Zhao X, Lu Y, Wu Y, Yao B, Liu J, Niu T, Wen Y, et al: Active antitumor immunity elicited by vaccine based on recombinant form of epidermal growth factor receptor. J Immunother. 2005, 28: 236-244. 10.1097/01.cji.0000161394.11831.3f.PubMed

43.

Wada S, Tsunoda T, Baba T, Primus FJ, Kuwano H, Shibuya M, Tahara H: Rationale for antiangiogenic cancer therapy with vaccination using epitope peptides derived from human vascular endothelial growth factor receptor 2. Cancer Res. 2005, 65: 4939-4946. 10.1158/0008-5472.CAN-04-3759.PubMed

44.

Tacken PJ, de Vries IJM, Torensma R, Figdor CG: Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nature Reviews Immunology. 2007, 7: 790-802. 10.1038/nri2173.PubMed

45.

Li Y, Wang MN, Li H, King KD, Bassi R, Sun H, Santiago A, Hooper AT, Bohlen P, Hicklin DJ: Active immunization against the vascular endothelial growth factor receptor flk1 inhibits tumor angiogenesis and metastasis. J Exp Med. 2002, 195: 1575-1584. 10.1084/jem.20020072.PubMedCentralPubMed

46.

Nair SK, Morse M, Boczkowski D, Cumming RI, Vasovic L, Gilboa E, Lyerly HK: Induction of tumor-specific cytotoxic T lymphocytes in cancer patients by autologous tumor RNA-Transfected dendritic cells. Annals of Surgery. 2002, 235: 540-549. 10.1097/00000658-200204000-00013.PubMedCentralPubMed

47.

Nair S, Boczkowski D, Moeller B, Dewhirst M, Vieweg J, Gilboa E: Synergy between tumor immunotherapy and antiangiogenic therapy. Blood. 2003, 102: 964-971. 10.1182/blood-2002-12-3738.PubMed

48.

Pellegatta S, Poliani PL, Stucchi E, Corno D, Colombo CA, Orzan F, Ravanini M, Finocchiaro G: Intra-tumoral dendritic cells increase efficacy of peripheral vaccination by modulation of glioma microenvironment. Neuro Oncol. 2010, 12: 377-388.PubMedCentralPubMed

49.

Lai MD, Yen MC, Lin CM, Tu CF, Wang CC, Lin PS, Yang HJ, Lin CC: The effects of DNA formulation and administration route on cancer therapeutic efficacy with xenogenic EGFR DNA vaccine in a lung cancer animal model. Genet Vaccines Ther. 2009, 7: 2-10.1186/1479-0556-7-2.PubMedCentralPubMed

50.

Wei YQ, Wang QR, Zhao X, Yang L, Tian L, Lu Y, Kang B, Lu CJ, Huang MJ, Lou YY, et al: Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine. Nat Med. 2000, 6: 1160-1166. 10.1038/80506.PubMed

51.

Okaji Y, Tsuno NH, Kitayama J, Saito S, Takahashi T, Kawai K, Yazawa K, Asakage M, Hori N, Watanabe T, et al: Vaccination with autologous endothelium inhibits angiogenesis and metastasis of colon cancer through autoimmunity. Cancer Science. 2004, 95: 85-90. 10.1111/j.1349-7006.2004.tb03175.x.PubMed

52.

Scappaticci FA, Nolan GP: Induction of anti-tumor immunity in mice using a syngeneic endothelial cell vaccine. Anticancer Res. 2003, 23: 1165-1172.PubMed

53.

Yoshiura K, Nishishita T, Nakaoka T, Yamashita N, Yamashita N: Inhibition of B16 melanoma growth and metastasis in C57BL mice by vaccination with a syngeneic endothelial cell line. Journal of Experimental & Clinical Cancer Research. 2009, 28: 13-

54.

Okaji Y, Tsuno NH, Tanaka M, Yoneyama S, Matsuhashi M, Kitayama J, Saito S, Nagura Y, Tsuchiya T, Yamada J, et al: Pilot study of anti-angiogenic vaccine using fixed whole endothelium in patients with progressive malignancy after failure of conventional therapy. European Journal of Cancer. 2008, 44: 383-390. 10.1016/j.ejca.2007.10.018.PubMed

55.

Zhang W, Liu JN, Tan XY: Vaccination with xenogeneic tumor endothelial proteins isolated in situ inhibits tumor angiogenesis and spontaneous metastasis. Int J Cancer. 2009, 125: 124-132. 10.1002/ijc.24362.PubMed

56.

Shalaby F, Rossant J, Yamaguchi TP, Gertsenstein M, Wu XF, Breitman ML, Schuh AC: Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature. 1995, 376: 62-66. 10.1038/376062a0.PubMed

57.

Taraboletti G, Margosio B: Antiangiogenic and antivascular therapy for cancer. Curr Opin Pharmacol. 2001, 1: 378-384. 10.1016/S1471-4892(01)00065-0.PubMed

58.

Wei YQ, Huang MJ, Yang L, Zhao X, Tian L, Lu Y, Shu JM, Lu CJ, Niu T, Kang B, et al: Immunogene therapy of tumors with vaccine based on Xenopus homologous vascular endothelial growth factor as a model antigen. Proc Natl Acad Sci USA. 2001, 98: 11545-11550. 10.1073/pnas.191112198.PubMedCentralPubMed

59.

Niethammer AG, Xiang R, Becker JC, Wodrich H, Pertl U, Karsten G, Eliceiri BP, Reisfeld RA: A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat Med. 2002, 8: 1369-1375. 10.1038/nm794.PubMed

60.

Hou JM, Liu JY, Yang L, Zhao X, Tian L, Ding ZY, Wen YJ, Niu T, Xiao F, Lou YY, et al: Combination of low-dose gemcitabine and recombinant quail vascular endothelial growth factor receptor-2 as a vaccine induces synergistic antitumor activities. Oncology. 2005, 69: 81-87. 10.1159/000087303.PubMed

61.

Zhou H, Luo Y, Mizutani M, Mizutani N, Reisfeld RA, Xiang R: T cell-mediated suppression of angiogenesis results in tumor protective immunity. Blood. 2005, 106: 2026-2032. 10.1182/blood-2005-03-0969.PubMed

62.

Dong Y, Qian J, Ibrahim R, Berzofsky JA, Khleif SN: Identification of H-2Db-specific CD8+ T-cell epitopes from mouse VEGFR2 that can inhibit angiogenesis and tumor growth. J Immunother. 2006, 29: 32-40. 10.1097/01.cji.0000175494.13476.56.PubMed

63.

Luo Y, Markowitz D, Xiang R, Zhou H, Reisfeld RA: FLK-1-based minigene vaccines induce T cell-mediated suppression of angiogenesis and tumor protective immunity in syngeneic BALB/c mice. Vaccine. 2007, 25: 1409-1415. 10.1016/j.vaccine.2006.10.043.PubMedCentralPubMed

64.

Wang YS, Wang GQ, Wen YJ, Wang L, Chen XC, Chen P, Kan B, Li J, Huang C, Lu Y, et al: Immunity against tumor angiogenesis induced by a fusion vaccine with murine beta-defensin 2 and mFlk-1. Clin Cancer Res. 2007, 13: 6779-6787. 10.1158/1078-0432.CCR-07-1587.PubMed

65.

Xie K, Bai RZ, Wu Y, Liu Q, Liu K, Wei YQ: Anti-tumor effects of a human VEGFR-2-based DNA vaccine in mouse models. Genet Vaccines Ther. 2009, 7: 10-10.1186/1479-0556-7-10.PubMedCentralPubMed

66.

Miyazawa M, Ohsawa R, Tsunoda T, Hirono S, Kawai M, Tani M, Nakamura Y, Yamaue H: Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer. Cancer Sci. 2010, 101: 433-439. 10.1111/j.1349-7006.2009.01416.x.PubMed

67.

Zuo SG, Chen Y, Wu ZP, Liu X, Liu C, Zhou YC, Wu CL, Jin CG, Gu YL, Li J, et al: Orally administered DNA vaccine delivery by attenuated Salmonella typhimurium targeting fetal liver kinase 1 inhibits murine Lewis lung carcinoma growth and metastasis. Biol Pharm Bull. 2010, 33: 174-182. 10.1248/bpb.33.174.PubMed

68.

Yang D, Chertov O, Bykovskaia SN, Chen Q, Buffo MJ, Shogan J, Anderson M, Schroder JM, Wang JM, Howard OM, Oppenheim JJ: Beta-defensins: linking innate and adaptive immunity through dendritic and T cell CCR6. Science. 1999, 286: 525-528. 10.1126/science.286.5439.525.PubMed

69.

Biragyn A, Ruffini PA, Leifer CA, Klyushnenkova E, Shakhov A, Chertov O, Shirakawa AK, Farber JM, Segal DM, Oppenheim JJ, Kwak LW: Toll-like receptor 4-dependent activation of dendritic cells by beta-defensin 2. Science. 2002, 298: 1025-1029. 10.1126/science.1075565.PubMed

70.

Lee YH, Tokunaga T, Oshika Y, Suto R, Yanagisawa K, Tomisawa M, Fukuda H, Nakano H, Abe S, Tateishi A, et al: Cell-retained isoforms of vascular endothelial growth factor (VEGF) are correlated with poor prognosis in osteosarcoma. Eur J Cancer. 1999, 35: 1089-1093. 10.1016/S0959-8049(99)00073-8.PubMed

71.

Oshika Y, Nakamura M, Tokunaga T, Ozeki Y, Fukushima Y, Hatanaka H, Abe Y, Yamazaki H, Kijima H, Tamaoki N, Ueyama Y: Expression of cell-associated isoform of vascular endothelial growth factor 189 and its prognostic relevance in non-small cell lung cancer. Int J Oncol. 1998, 12: 541-544.PubMed

72.

Li XH, Tang L, Liu D, Sun HM, Zhou CC, Tan LS, Wang LP, Zhang PD, Zhang SQ: [Antitumor effect of recombinant T7 phage vaccine expressing xenogenic vascular endothelial growth factor on Lewis lung cancer in mice]. Ai Zheng. 2006, 25: 1221-1226.PubMed

73.

Rad FH, Le Buanec H, Paturance S, Larcier P, Genne P, Ryffel B, Bensussan A, Bizzini B, Gallo RC, Zagury D, Uzan G: VEGF kinoid vaccine, a therapeutic approach against tumor angiogenesis and metastases. Proc Natl Acad Sci USA. 2007, 104: 2837-2842. 10.1073/pnas.0611022104.PubMedCentralPubMed

74.

Harper SJ, Bates DO: VEGF-A splicing: the key to anti-angiogenic therapeutics?. Nat Rev Cancer. 2008, 8: 880-887. 10.1038/nrc2505.PubMedCentralPubMed

75.

Varey AH, Rennel ES, Qiu Y, Bevan HS, Perrin RM, Raffy S, Dixon AR, Paraskeva C, Zaccheo O, Hassan AB, et al: VEGF 165 b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy. Br J Cancer. 2008, 98: 1366-1379. 10.1038/sj.bjc.6604308.PubMedCentralPubMed

76.

Plum SM, Holaday JW, Ruiz A, Madsen JW, Fogler WE, Fortier AH: Administration of a liposomal FGF-2 peptide vaccine leads to abrogation of FGF-2-mediated angiogenesis and tumor development. Vaccine. 2000, 19: 1294-1303. 10.1016/S0264-410X(00)00210-3.PubMed

77.

Plum SM, Vu HA, Mercer B, Fogler WE, Fortier AH: Generation of a specific immunological response to FGF-2 does not affect wound healing or reproduction. Immunopharmacol Immunotoxicol. 2004, 26: 29-41. 10.1081/IPH-120029942.PubMed

78.

He QM, Wei YQ, Tian L, Zhao X, Su JM, Yang L, Lu Y, Kan B, Lou YY, Huang MJ, et al: Inhibition of tumor growth with a vaccine based on xenogeneic homologous fibroblast growth factor receptor-1 in mice. J Biol Chem. 2003, 278: 21831-21836. 10.1074/jbc.M300880200.PubMed

79.

Nanda A, Carson-Walter EB, Seaman S, Barber TD, Stampfl J, Singh S, Vogelstein B, Kinzler KW, St Croix B: TEM8 interacts with the cleaved C5 domain of collagen alpha 3(VI). Cancer Res. 2004, 64: 817-820. 10.1158/0008-5472.CAN-03-2408.PubMed

80.

Carson-Walter EB, Watkins DN, Nanda A, Vogelstein B, Kinzler KW, St Croix B: Cell surface tumor endothelial markers are conserved in mice and humans. Cancer Res. 2001, 61: 6649-6655.PubMed

81.

Venanzi FM, Petrini M, Fiammenghi L, Bolli E, Granato AM, Ridolfi L, Gabrielli F, Barucca A, Concetti A, Ridolfi R, Riccobon A: Tumor endothelial marker 8 expression levels in dendritic cell-based cancer vaccines are related to clinical outcome. Cancer Immunol Immunother. 2010, 59: 27-34. 10.1007/s00262-009-0717-4.PubMed

82.

Felicetti P, Mennecozzi M, Barucca A, Montgomery S, Orlandi F, Manova K, Houghton AN, Gregor PD, Concetti A, Venanzi FM: Tumor endothelial marker 8 enhances tumor immunity in conjunction with immunization against differentiation Ag. Cytotherapy. 2007, 9: 23-34. 10.1080/14653240601048369.

83.

Ruan Z, Yang Z, Wang Y, Wang H, Chen Y, Shang X, Yang C, Guo S, Han J, Liang H, Wu Y: DNA vaccine against tumor endothelial marker 8 inhibits tumor angiogenesis and growth. J Immunother. 2009, 32: 486-491. 10.1097/CJI.0b013e3181a1d134.PubMed

84.

Dales JP, Garcia S, Andrac L, Carpentier S, Ramuz O, Lavaut MN, Allasia C, Bonnier P, Charpin C: Prognostic significance of angiogenesis evaluated by CD105 expression compared to CD31 in 905 breast carcinomas: correlation with long-term patient outcome. Int J Oncol. 2004, 24: 1197-1204.PubMed

85.

Takahashi N, Kawanishi-Tabata R, Haba A, Tabata M, Haruta Y, Tsai H, Seon BK: Association of serum endoglin with metastasis in patients with colorectal, breast, and other solid tumors, and suppressive effect of chemotherapy on the serum endoglin. Clin Cancer Res. 2001, 7: 524-532.PubMed

86.

Hofmeister V, Schrama D, Becker JC: Anti-cancer therapies targeting the tumor stroma. Cancer Immunol Immunother. 2008, 57: 1-17. 10.1007/s00262-007-0365-5.PubMed

87.

Tan GH, Wei YQ, Tian L, Zhao X, Yang L, Li J, He QM, Wu Y, Wen YJ, Yi T, et al: Active immunotherapy of tumors with a recombinant xenogeneic endoglin as a model antigen. Eur J Immunol. 2004, 34: 2012-2021. 10.1002/eji.200424933.PubMed

88.

Tan GH, Tian L, Wei YQ, Zhao X, Li J, Wu Y, Wen YJ, Yi T, Ding ZY, Kan B, et al: Combination of low-dose cisplatin and recombinant xenogeneic endoglin as a vaccine induces synergistic antitumor activities. Int J Cancer. 2004, 112: 701-706. 10.1002/ijc.20449.PubMed

89.

Troyanovsky B, Levchenko T, Mansson G, Matvijenko O, Holmgren L: Angiomotin: an angiostatin binding protein that regulates endothelial cell migration and tube formation. J Cell Biol. 2001, 152: 1247-1254. 10.1083/jcb.152.6.1247.PubMedCentralPubMed

90.

Bratt A, Birot O, Sinha I, Veitonmaki N, Aase K, Ernkvist M, Holmgren L: Angiomotin regulates endothelial cell-cell junctions and cell motility. J Biol Chem. 2005, 280: 34859-34869. 10.1074/jbc.M503915200.PubMed

91.

Jiang WG, Watkins G, Douglas-Jones A, Holmgren L, Mansel RE: Angiomotin and angiomotin like proteins, their expression and correlation with angiogenesis and clinical outcome in human breast cancer. BMC Cancer. 2006, 6: 16-10.1186/1471-2407-6-16.PubMedCentralPubMed

92.

Peters KG, Coogan A, Berry D, Marks J, Iglehart JD, Kontos CD, Rao P, Sankar S, Trogan E: Expression of Tie2/Tek in breast tumour vasculature provides a new marker for evaluation of tumour angiogenesis. Br J Cancer. 1998, 77: 51-56. 10.1038/bjc.1998.8.PubMedCentralPubMed

93.

Lin P, Buxton JA, Acheson A, Radziejewski C, Maisonpierre PC, Yancopoulos GD, Channon KM, Hale LP, Dewhirst MW, George SE, Peters KG: Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2. Proc Natl Acad Sci USA. 1998, 95: 8829-8834. 10.1073/pnas.95.15.8829.PubMedCentralPubMed

94.

Luo Y, Wen YJ, Ding ZY, Fu CH, Wu Y, Liu JY, Li Q, He QM, Zhao X, Jiang Y, et al: Immunotherapy of tumors with protein vaccine based on chicken homologous Tie-2. Clin Cancer Res. 2006, 12: 1813-1819. 10.1158/1078-0432.CCR-05-1990.PubMed

95.

Ramage JM, Metheringham R, Conn A, Spendlove I, Moss RS, Patton DT, Murray JC, Rees RC, Durrant LG: Identification of an HLA-A*0201 cytotoxic T lymphocyte epitope specific to the endothelial antigen Tie-2. Int J Cancer. 2004, 110: 245-250. 10.1002/ijc.20120.PubMed

96.

Fu C, Bardhan S, Cetateanu ND, Wamil BD, Wang Y, Yan HP, Shi E, Carter C, Venkov C, Yakes FM, et al: Identification of a novel membrane protein, HP59, with therapeutic potential as a target of tumor angiogenesis. Clin Cancer Res. 2001, 7: 4182-4194.PubMed

97.

Rojas J, Green RS, Hellerqvist CG, Olegard R, Brigham KL, Stahlman MT: Studies on group B beta-hemolytic Streptococcus. II. Effects on pulmonary hemodynamics and vascular permeability in unanesthetized sheep. Pediatr Res. 1981, 15: 899-904.PubMed

98.

Sundell HW, Yan H, Carter CE, Wamil BD, Wu K, Gaddipati R, Li D, Hellerqvist CG: Isolation and identification of the group B streptococcal toxin CM101 from infants with sepsis. J Pediatr. 2000, 137: 338-344. 10.1067/mpd.2000.107839.PubMed

99.

Funa K, Uramoto H: Regulatory mechanisms for the expression and activity of platelet-derived growth factor receptor. Acta Biochim Pol. 2003, 50: 647-658.PubMed

100.

Ostman A: PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma. Cytokine Growth Factor Rev. 2004, 15: 275-286. 10.1016/j.cytogfr.2004.03.002.PubMed

101.

Song S, Ewald AJ, Stallcup W, Werb Z, Bergers G: PDGFRbeta+ perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival. Nat Cell Biol. 2005, 7: 870-879. 10.1038/ncb1288.PubMedCentralPubMed

102.

Fest S, Huebener N, Bleeke M, Durmus T, Stermann A, Woehler A, Baykan B, Zenclussen AC, Michalsky E, Jaeger IS, et al: Survivin minigene DNA vaccination is effective against neuroblastoma. Int J Cancer. 2009, 125: 104-114. 10.1002/ijc.24291.PubMed

103.

Hajri A, Balboni G, Koenig M, Garaud JC, Damge C: Gastrin-releasing peptide: in vivo and in vitro growth effects on an acinar pancreatic carcinoma. Cancer Res. 1992, 52: 3726-3732.PubMed

104.

Lango MN, Dyer KF, Lui VW, Gooding WE, Gubish C, Siegfried JM, Grandis JR: Gastrin-releasing peptide receptor-mediated autocrine growth in squamous cell carcinoma of the head and neck. J Natl Cancer Inst. 2002, 94: 375-383.PubMed

105.

Kim S, Hu W, Kelly DR, Hellmich MR, Evers BM, Chung DH: Gastrin-releasing peptide is a growth factor for human neuroblastomas. Ann Surg. 2002, 235: 621-629. 10.1097/00000658-200205000-00003. discussion 629-630PubMedCentralPubMed

106.

Cuttitta F, Carney DN, Mulshine J, Moody TW, Fedorko J, Fischler A, Minna JD: Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer. Nature. 1985, 316: 823-826. 10.1038/316823a0.PubMed

107.

Carney DN, Cuttitta F, Moody TW, Minna JD: Selective stimulation of small cell lung cancer clonal growth by bombesin and gastrin-releasing peptide. Cancer Res. 1987, 47: 821-825.PubMed

108.

Yano T, Pinski J, Groot K, Schally AV: Stimulation by bombesin and inhibition by bombesin/gastrin-releasing peptide antagonist RC-3095 of growth of human breast cancer cell lines. Cancer Res. 1992, 52: 4545-4547.PubMed

109.

Vangsted AJ, Andersen EV, Nedergaard L, Zeuthen J: Gastrin releasing peptide GRP(14-27) in human breast cancer cells and in small cell lung cancer. Breast Cancer Res Treat. 1991, 19: 119-128. 10.1007/BF01980942.PubMed

110.

Scott N, Millward E, Cartwright EJ, Preston SR, Coletta PL: Gastrin releasing peptide and gastrin releasing peptide receptor expression in gastrointestinal carcinoid tumours. J Clin Pathol. 2004, 57: 189-192. 10.1136/jcp.2003.10660.PubMedCentralPubMed

111.

Martinez A, Zudaire E, Julian M, Moody TW, Cuttitta F: Gastrin-releasing peptide (GRP) induces angiogenesis and the specific GRP blocker 77427 inhibits tumor growth in vitro and in vivo. Oncogene. 2005, 24: 4106-4113.PubMed

112.

Levine L, Lucci JA, Pazdrak B, Cheng JZ, Guo YS, Townsend CM, Hellmich MR: Bombesin stimulates nuclear factor kappa B activation and expression of proangiogenic factors in prostate cancer cells. Cancer Res. 2003, 63: 3495-3502.PubMed

113.

Kang J, Ishola TA, Baregamian N, Mourot JM, Rychahou PG, Evers BM, Chung DH: Bombesin induces angiogenesis and neuroblastoma growth. Cancer Lett. 2007, 253: 273-281. 10.1016/j.canlet.2007.02.007.PubMedCentralPubMed

114.

Cornelio DB, Roesler R, Schwartsmann G: Gastrin-releasing peptide receptor as a molecular target in experimental anticancer therapy. Ann Oncol. 2007, 18: 1457-1466. 10.1093/annonc/mdm058.PubMed

115.

Guojun W, Wei G, Kedong O, Yi H, Yanfei X, Qingmei C, Yankai Z, Jie W, Hao F, Taiming L, et al: A novel vaccine targeting gastrin-releasing peptide: efficient inhibition of breast cancer growth in vivo. Endocr Relat Cancer. 2008, 15: 149-159. 10.1677/ERC-07-0224.PubMed

116.

Fang J, Lu Y, Ouyang K, Wu G, Zhang H, Liu Y, Chen Y, Lin M, Wang H, Jin L, et al: Specific antibodies elicited by a novel DNA vaccine targeting gastrin-releasing peptide inhibit murine melanoma growth in vivo. Clin Vaccine Immunol. 2009, 16: 1033-1039. 10.1128/CVI.00046-09.PubMedCentralPubMed

117.

Liu C, Sun C, Huang H, Janda K, Edgington T: Overexpression of legumain in tumors is significant for invasion/metastasis and a candidate enzymatic target for prodrug therapy. Cancer Res. 2003, 63: 2957-2964.PubMed

118.

Murthy RV, Arbman G, Gao J, Roodman GD, Sun XF: Legumain expression in relation to clinicopathologic and biological variables in colorectal cancer. Clin Cancer Res. 2005, 11: 2293-2299. 10.1158/1078-0432.CCR-04-1642.PubMed

119.

Luo Y, Zhou H, Krueger J, Kaplan C, Lee SH, Dolman C, Markowitz D, Wu W, Liu C, Reisfeld RA, Xiang R: Targeting tumor-associated macrophages as a novel strategy against breast cancer. J Clin Invest. 2006, 116: 2132-2141. 10.1172/JCI27648.PubMedCentralPubMed

120.

Lewen S, Zhou H, Hu HD, Cheng T, Markowitz D, Reisfeld RA, Xiang R, Luo Y: A Legumain-based minigene vaccine targets the tumor stroma and suppresses breast cancer growth and angiogenesis. Cancer Immunol Immunother. 2008, 57: 507-515. 10.1007/s00262-007-0389-x.PubMed

121.

Rasmussen HS, McCann PP: Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat. Pharmacol Ther. 1997, 75: 69-75. 10.1016/S0163-7258(97)00023-5.PubMed

122.

Anderson IC, Shipp MA, Docherty AP, Teicher BA: Combination therapy including a gelatinase inhibitor and cytoxic agent reduces local invasion and metastasis of murine Lewis lung carcinoma. Cancer Research. 1996, 56: 715-718.PubMed

123.

Su JM, Wei YQ, Tian L, Zhao X, Yang L, He QM, Wang Y, Lu Y, Wu Y, Liu F, et al: Active immunogene therapy of cancer with vaccine on the basis of chicken homologous matrix metalloproteinase-2. Cancer Res. 2003, 63: 600-607.PubMed

124.

Smyth E: The Trouble with Inhibitors. Signalling scissors: new perspectives on proteases; Brescia, Italy. 2003, Nature Publishing Group

125.

Dove A: MMP inhibitors: glimmers of hope amidst clinical failures. Nat Med. 2002, 8: 95-10.1038/nm0202-95.PubMed

126.

Overall CM, Kleifeld O: Towards third generation matrix metalloproteinase inhibitors for cancer therapy. Br J Cancer. 2006, 94: 941-946. 10.1038/sj.bjc.6603043.PubMedCentralPubMed

127.

Overall CM, Kleifeld O: Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer. 2006, 6: 227-239. 10.1038/nrc1821.PubMed

128.

Eskens FA, Dumez H, Hoekstra R, Perschl A, Brindley C, Bottcher S, Wynendaele W, Drevs J, Verweij J, van Oosterom AT: Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours. Eur J Cancer. 2003, 39: 917-926. 10.1016/S0959-8049(03)00057-1.PubMed

129.

Lou YY, Wei YQ, Yang L, Zhao X, Tian L, Lu Y, Wen YJ, Liu F, Huang MJ, Kang B, et al: Immunogene therapy of tumors with a vaccine based on the ligand-binding domain of chicken homologous integrin beta3. Immunol Invest. 2002, 31: 51-69. 10.1081/IMM-120003221.PubMed

130.

Liu JY, Wei YQ, Yang L, Zhao X, Tian L, Hou JM, Niu T, Liu F, Jiang Y, Hu B, et al: Immunotherapy of tumors with vaccine based on quail homologous vascular endothelial growth factor receptor-2. Blood. 2003, 102: 1815-1823. 10.1182/blood-2002-12-3772.PubMed

131.

Dirix LY, Van Dam PA, Prove PA, Vermeulen PB: Bevacizumab in the Treatment of Patients with Advanced Breast Cancer: Where have We Landed?. Ther Adv Med Oncol. 2010, 2: 331-342. 10.1177/1758834010376301.PubMedCentralPubMed

132.

Bielawska-Pohl A, Crola C, Caignard A, Gaudin C, Dus D, Kieda C, Chouaib S: Human NK cells lyse organ-specific endothelial cells: analysis of adhesion and cytotoxic mechanisms. J Immunol. 2005, 174: 5573-5582.PubMed

133.

Tsuji K, Hamada T, Uenaka A, Wada H, Sato E, Isobe M, Asagoe K, Yamasaki O, Shiku H, Ritter G, et al: Induction of immune response against NY-ESO-1 by CHP-NY-ESO-1 vaccination and immune regulation in a melanoma patient. Cancer Immunol Immunother. 2008, 57: 1429-1437. 10.1007/s00262-008-0478-5.PubMed

134.

Ostrand-Rosenberg S: Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity. Cancer Immunol Immunother. 2010, 59: 1593-1600. 10.1007/s00262-010-0855-8.PubMedCentralPubMed

135.

Bielawska-Pohl A, Blesson S, Benlalam H, Trenado A, Opolon P, Bawa O, Rouffiac V, Dus D, Kieda C, Chouaib S: The anti-angiogenic activity of IL-12 is increased in iNOS-/- mice and involves NK cells. J Mol Med. 2010, 88: 775-784. 10.1007/s00109-010-0620-7.PubMed

136.

Osada T, Clay T, Hobeika A, Lyerly HK, Morse MA: NK cell activation by dendritic cell vaccine: a mechanism of action for clinical activity. Cancer Immunol Immunother. 2006, 55: 1122-1131. 10.1007/s00262-005-0089-3.PubMed

137.

Sidky YA, Borden EC: Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses. Cancer Res. 1987, 47: 5155-5161.PubMed

138.

Majewski S, Szmurlo A, Marczak M, Jablonska S, Bollag W: Synergistic effect of retinoids and interferon alpha on tumor-induced angiogenesis: anti-angiogenic effect on HPV-harboring tumor-cell lines. Int J Cancer. 1994, 57: 81-85. 10.1002/ijc.2910570115.PubMed

139.

Slaton JW, Perrotte P, Inoue K, Dinney CP, Fidler IJ: Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin Cancer Res. 1999, 5: 2726-2734.PubMed

140.

Benlalam H, Jalil A, Hasmim M, Pang B, Tamouza R, Mitterrand M, Godet Y, Lamerant N, Robert C, Avril MF, et al: Gap junction communication between autologous endothelial and tumor cells induce cross-recognition and elimination by specific CTL. J Immunol. 2009, 182: 2654-2664. 10.4049/jimmunol.0800815.PubMed

141.

Arap W, Haedicke W, Bernasconi M, Kain R, Rajotte D, Krajewski S, Ellerby HM, Bredesen DE, Pasqualini R, Ruoslahti E: Targeting the prostate for destruction through a vascular address. Proc Natl Acad Sci USA. 2002, 99: 1527-1531. 10.1073/pnas.241655998.PubMedCentralPubMed

142.

Trepel M, Arap W, Pasqualini R: In vivo phage display and vascular heterogeneity: implications for targeted medicine. Curr Opin Chem Biol. 2002, 6: 399-404. 10.1016/S1367-5931(02)00336-8.PubMed

143.

Ruoslahti E, Duza T, Zhang L: Vascular homing peptides with cell-penetrating properties. Curr Pharm Des. 2005, 11: 3655-3660. 10.2174/138161205774580787.PubMed

Title: Vaccines targeting the neovasculature of tumors
Authors: Agata Matejuk
Qixin Leng
Szu-Ting Chou
Archibald J Mixson
Publication date: 01-12-2011
Publisher: BioMed Central
Published in: Vascular Cell / Issue 1/2011
Electronic ISSN: 2045-824X
DOI: https://doi.org/10.1186/2045-824X-3-7

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Vaccines targeting the neovasculature of tumors

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2011

Anti-DLL4, a cancer therapeutic with multiple mechanisms of action

Cyclic strain upregulates VEGF and attenuates proliferation of vascular smooth muscle cells

Co-culture of Retinal and Endothelial Cells Results in the Modulation of Genes Critical to Retinal Neovascularization

Application of microtechnologies for the vascularization of engineered tissues

Effects on duration of post-operative ischemia and patterns of blood flow recovery in different conditions of mouse hind limb ischemia

Nanotechnology-mediated targeting of tumor angiogenesis

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page